Showing results (121-130 of 176) with videos related to

Sort By:
Pageof 18
Cancer|February 26, 2013
Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancerPhillip J Gray, Jonathan J Paly, Beow Y Yeap, et al.
Lung Cancer (Amsterdam, Netherlands)|June 30, 2014
Aggressive therapy for patients with non-small cell lung carcinoma and synchronous brain-only oligometastatic disease is associated with long-term survivalPhillip J Gray, Raymond H Mak, Beow Y Yeap, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2007
Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancerDavid M Jackman, Beow Y Yeap, Neal I Lindeman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2026
Dose Escalation With Intensity-Modulated Proton Therapy for Patients with High-Risk Meningiomas - Results From a Phase 1 TrialFelix Ehret, Nora K Horick, Beow Y Yeap, et al.
JCO Clinical Cancer Informatics|March 19, 2025
Predictive Model of Acute Rectal Toxicity in Prostate Cancer Treated With RadiotherapyKeyur D Shah, Beow Y Yeap, Hoyeon Lee, et al.
International Journal of Radiation Oncology, Biology, Physics|December 20, 2008
Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomasThomas F DeLaney, Norbert J Liebsch, Francis X Pedlow, et al.
International Journal of Radiation Oncology, Biology, Physics|February 8, 2021
Circulating Lymphocyte Counts Early During Radiation Therapy Are Associated With Recurrence in Pediatric MedulloblastomaClemens Grassberger, Daniel Shinnick, Beow Y Yeap, et al.
Cancer|January 15, 2015
Proton therapy for low-grade gliomas: Results from a prospective trialHelen A Shih, Janet C Sherman, Lisa B Nachtigall, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2013
ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancerJustin F Gainor, Anna M Varghese, Sai-Hong Ignatius Ou, et al.
The American Journal of Pathology|May 22, 2010
Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasisElisa Benedettini, Lynette M Sholl, Michael Peyton, et al.
Pageof 18